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Aurora-A is a serine/threonine kinase that plays critical roles in centrosomematuration, spin-
dle dynamics, and chromosome orientation and it is frequently over-expressed in human
cancers. In this work, we show that Aurora-A interacts with the SUMO-conjugating enzyme
UBC9 and co-localizes with SUMO1 in mitotic cells. Aurora-A can be SUMOylated in vitro
and in vivo. Mutation of the highly conserved SUMOylation residue lysine 249 signiﬁcantly
disrupts Aurora-A SUMOylation and mitotic defects characterized by defective and mul-
tipolar spindles ensue. The Aurora-AK249R mutant has normal kinase activity but displays
altered dynamics at the mitotic spindle. In addition, ectopic expression of theAurora-AK249R
mutant results in a signiﬁcant increase in susceptibility tomalignant transformation induced
by the Ras oncogene. These data suggest that modiﬁcation by SUMO residues may con-
trol Aurora-A function at the spindle and that deﬁciency of SUMOylation of this kinase may
have important implications for tumor development.
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INTRODUCTION
Aurora-A is a serine/threonine kinase with important functions
in the biology of centrosomes and chromosomes. This protein
belongs to the Aurora kinase family composed of Aurora-A, -B,
and -C in mammals (Carmena and Earnshaw, 2003). Despite their
sequence similarity, the three mammalianAurora family members
differ in their expression patterns, sub-cellular localization, timing
of activity, and roles in cancer development and progression. Dys-
function of these kinases has been associated with defects in the
chromosome content of cells that contribute to genetic instabil-
ity. Among the three Aurora kinases, over-expression of Aurora-A
in human cancer was ﬁrst described in primary breast and colon
tumor cells (Sen et al., 1997; Bischoff et al., 1998). Over-expression
of this protein induces abnormal centrosome duplication and the
subsequent formation of abnormal spindle structures, leading to
abnormal chromosome segregation (Zhou et al., 1998; Meraldi
et al., 2002). Aurora-A has also been found to be ampliﬁed in a
subset of human tumors, and was localized to an amplicon associ-
ated with poor prognosis in patients with breast and colon tumors
(20q13; Bischoff et al., 1998; Royce et al., 2004). Many subsequent
studies have identiﬁed other tumor types, including pancreatic,
ovarian bladder, gastric, and thyroid tumors, in which Aurora-A
is over-expressed (Miyoshi et al., 2001; Sakakura et al., 2001; Sen
et al., 2002; Gritsko et al., 2003; Li et al., 2003; Moreno-Bueno
et al., 2003). It has also been demonstrated that some Aurora-A
variants confer low-penetrance susceptibility to tumor develop-
ment and progression in mices and humans (Ewart-Toland et al.,
2003).All these results have aroused interest inAurora-A as a puta-
tive oncogene and as an attractive anti-tumoral therapeutic target
(Katayama et al., 2003; Perez De Castro et al., 2008; Lens et al.,
2010).
Aurora-A is mainly localized on duplicated centrosomes from
the end of the S phase until the beginning of the following G1
phase (Marumoto et al., 2005). Its protein levels seem to be cell
cycle regulated as it is synthesized and activated at the end of
S phase with a peak in the G2/M phase, and, it is degraded via
the ubiquitin/proteasome pathway as cells enter into the next
G1 phase (Castro et al., 2002; Taguchi et al., 2002). The kinase
activity of the Aurora-A protein is regulated by phosphoryla-
tion at several residues including Ser 51, Thr 288, and Ser 342
(Littlepage et al., 2002; Eyers et al., 2003; Kitajima et al., 2007).
Degradation of the protein requires the presence of speciﬁc amino
acids in the C terminal sequence (destruction box – RxxLxD)
and the dephosphorylation of Ser 51 (Arlot-Bonnemains et al.,
2001; Kitajima et al., 2007). Whether Aurora-A is subject to other
post-translational modiﬁcations is unknown at present.
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Among the post-translational modiﬁcations that regulate pro-
tein behavior, SUMOylation is characterized by its highly dynamic
and reversible nature. Similar to ubiquitination, SUMOylation
modulates protein function through post-translational covalent
attachment of Small Ubiquitin-related MOdiﬁers (SUMOs) to
lysine residues within targeted proteins. Although invertebrates
express a single SUMO protein, three paralogs exist in verte-
brates: SUMO1,SUMO2,andSUMO3. SUMOconjugation,which
often requires the consensus sequence ψKxE/D (where ψ is a
large hydrophobic residue and x is any amino acid), occurs in a
stepwise enzymatic cascade (Melchior,2000;Hay,2005). The cova-
lent attachment of SUMO to lysine residues is catalyzed by three
types of enzymes, a SUMO-activating E1 enzyme (Aos1/Uba2), a
SUMO-conjugating E2 enzyme (UBC9), and a SUMO E3 ligase.
SUMOylation has been shown to play a crucial role in regulat-
ing the activity of numerous cellular processes, including nuclear
transport, genome integrity, signal transduction, and transcrip-
tional regulation (Hay, 2005; Ulrich, 2008). An increasing num-
ber of studies have demonstrated that SUMOylation is essential
for regulating chromosome segregation and progression through
mitosis (Dasso, 2008). In yeast and Drosophila, SUMOylation has
been shown to be critical for chromosome condensation, sister
chromatid cohesion, kinetochore function, and mitotic spindle
elongation (Watts, 2007). Multiple studies have conﬁrmed the
essential role of SUMOmodiﬁcation in progression throughmito-
sis in vertebrates (Dawlaty et al., 2008; Zhang et al., 2008b; Klein
et al., 2009). More recently, we demonstrated that SUMOyla-
tion of Aurora-B at Lysine 207 controls its proper localization
and activity at centromeres (Fernandez-Miranda et al., 2010).
Because this residue resides in a conserved SUMOylation motif
in all Aurora kinases we decided to analyze the possibility that
SUMO modiﬁcation is also involved in the regulation of Aurora-A
function.
In this manuscript, we report that Aurora-A interacts with the
SUMOylation machinery. Aurora-A interacts with the SUMO-
conjugating enzyme UBC9 and binds SUMO1 both in vitro and
in vivo. Mutation of the predicted SUMO-binding site, Lys249,
signiﬁcantly disrupts Aurora-A SUMOylation and results in sev-
eral aberrations during mitosis that are accompanied by defective
bipolar spindle formation. These defects have consequences for
the susceptibility of mutant cells to malignant transformation
by the Ras oncogene, suggesting a possible link between SUMO
modiﬁcation and the role of Aurora-A in cancer.
MATERIALS AND METHODS
YEAST TWO-HYBRID, IN VITRO SUMOYLATION AND PULL-DOWN
ASSAYS
The full-length human Aurora-A sequence was subcloned and
expressed as fusion protein with DNA-binding domain (pGBT9)
with a selection medium Trp. The human fetal kidney MATCH-
MAKER cDNA Library was cDNA protein expressed as fusion
with activation domain cloned in pACT2 vector library with
a selection medium Leu. Yeast strain CG1945 was transformed
by means of pairwise combination of both two-hybrid vectors
and grown on a medium without leucine or tryptophan. Galac-
tosidase activities were assayed using 5-bromo-4-chloro-3-indolyl
b-d-galactopyranoside staining on ﬁlter replicates according to
Breeden and Nasmyth (1985). Both pACT2 and pGBT9 vec-
tors without insert were used as negative controls. The human
UBC9 cDNA was obtained from MRC Geneservice (#14227-h18),
then subcloned into a pGEX-4T-1 vector (Amersham Biosciences,
#27-4580-01) in order to produce the recombinant GST–UBC9
full-length protein. All constructs were sequenced in full (Genome
Express).
Aurora-A(His)6 and GST-UBC9 recombinant proteins were
prepared as previously described (Smith and Johnson, 1988; Roghi
et al., 1998). Histidine-tagged proteins and proteins bound to
histidine-tagged proteins as well as GST–UBC9 and GST–UBC9
bound proteins were isolated by afﬁnity chromatography on
Nickel–NTA–agarose and GST–4B agarose, respectively. Proteins
from pull-downs were separated on 12.5% SDS polyacrylamide
gels and submitted to western blot using the appropriated anti-
bodies against Aurora-A (Abcam, mouse monoclonal 35C1 clone;
1/200) or GST (SIGMA, mouse monoclonal, #G1160, 1/50000).
The mouse Aurora-A cDNA was cloned into pENTR–DTOPO
vector using TOPO technology (Invitrogen) and transferred to a
destiny vector coexpressing EGFP or V5 tag by a LR recombina-
tion reaction of the Gateway system (Invitrogen). Mouse Aurora-
A mutants (Aurora-AK153M and Aurora-AK249R) were prepared
using theQuick-Change site-directedmutagenesis kit (Stratagene)
and were veriﬁed by DNA sequencing.
In vitro SUMOylation of recombinant Aurora-A protein was
tested using Active Motif SUMO link (Active Motif, #40120) and
following manufacturer’s conditions. Products from the in vitro
reaction were separated on 12% SDS-PAGE gels stained with
Coomassie and transferred to nitrocellulose membranes for the
further detection of Aurora-A and SUMO1 proteins using the cor-
responding antibodies (35C1 for Aurora-A at 1/200; Active Motif,
rabbit anti-SUMO1 at 1/4000). The reactions were performed in
the presence of SUMO1 or a SUMO1 non-conjugatable mutant.
SEQUENCE ANALYSIS
For protein domain analysis we ﬁrst used the eukaryotic lin-
ear motif (ELM1) algorithm. To further conﬁrm the presence of
SUMO motifs we used the speciﬁc SUMO prediction software
SUMOplot™Analysis Program2.
CELL CULTURE, TRANSFECTION, AND CELLULAR ASSAYS
HEK293, U2OS, and HeLa human cells were maintained in
DMEM medium supplemented with 10% fetal bovine serum and
antibiotics andwere grownat 37˚C in ahumidiﬁed5%CO2 atmos-
phere. NIH-3T3 mouse cells were maintained in the same condi-
tionswith 10%calf serum. In the focus-formation assaysNIH-3T3
cells were transfected with 10 μg of V5-Aurora-A plasmids and
1μg of H-Ras G12V following standard calcium phosphate trans-
fection protocol, maintained in culture during 3weeks and then
stained with crystal violet solution for foci quantiﬁcation. Cell
cycle distribution of cell lines were determined by ﬂow cytometry
after DNA staining with propidium iodide (Sigma) and analyzed
on a FACSCanto ﬂow cytometer (Becton Dickinson). Data were
processed using FACSDiva software (Becton Dickinson).
1http://elm.eu.org
2http://www.abgent.com/tools/SUMOplot
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To obtain HeLa cells stably expressing EGFP-tagged Aurora-
A variants, cells were transfected with EGFP–Aurora-A express-
ing vectors that also confer resistance to G418. To select stable
clones, G418 (1mg/ml) was added to the cultures for 10 days.
G418-resistant cells were then individually seeded in 96-well
microplates. EGFP-positive colonies were expanded and Aurora-
A exogenous expression established by immunoﬂuorescence and
immunoblotting (Figure A2 in Appendix).
For the taxol sensitive assay HeLa clones expressing EGFP–
Aurora-A variants in a stable fashion were treated with 150 nM
taxol for 48 h. The percentage of apoptotic cells was then mea-
sured using propidium iodide (PI) staining and ﬂow cytometry to
quantify the PI positive (dead) population.
The microtubule re-growth assay was performed using HeLa
cells stably expressing EGFP–Aurora-A variants, which were
treated with 100 ng/ml nocodazole for 6 h to enrich them at
M phase. Cells, in Hepes 10mM, were incubated on ice for
30min and then the microtubules (MT) were allowed to grow
by re-warming the cells at 37˚C. At different time points post re-
warming, cells were ﬁxed with 4% paraformaldehyde and cold
methanol.MTandcentrosomesweredetectedusing antiα-tubulin
from Sigma (DM1A; 1/1000) and α-CEP135 (kindly provided by
Dr.AnthonyHymanMaxPlank Institute of MolecularCell Biology
and Genetics, Dresden, Germany; Bird and Hyman, 2008; 1/500).
For the determination of chromosome numbers, metaphase
preparations were made using 0.075M KCl hypotonic treatment
and methanol/acetic acid ﬁxation from mouse ﬁbroblasts after a
2 h treatment with colcemid (0.01μg/ml). Slides were stainedwith
5% Giemsa in pH 6.8 buffer for 10min. Chromosome numbers
were scored in aminimumof 20metaphases in each type analyzed.
PROTEIN EXTRACTION AND ANALYSIS: IMMUNOPRECIPITATION,
DETECTION OF SUMOYLATION IN VIVO, AND IN VITRO KINASE ASSAYS
For immunodetection in protein lysates, cells were washed twice
with ice-cold PBS and lysed in RIPA lysis buffer (37mM NaCl,
0.5% NP-40, 0.1% SDS, 1% TX-100, 20mM Tris–HCl pH 7.4,
2mM EDTA, 10% glycerol 1mM PMSF) supplemented with pro-
tease and phosphatase inhibitory cocktails (Sigma). Additionally,
N -ethylmaleimide, an inhibitor of SUMO-proteases, was added
at 10mM ﬁnal concentration. After 30min on ice, samples were
cleared by centrifugation. Proteins were separated on SDS-PAGE,
transferred to nitrocellulose membranes (BioRad), probed using
speciﬁc antibody and detected using ﬂuorescent donkey (Rock-
land) or goat (Invitrogen) anti rabbit or anti mouse secondary
antibodies followed detection using the Odyssey Infrared Imag-
ing System (Li-Cor Biosciences). Primary antibodies used were
against Aurora-A (AbCam mouse monoclonal, clone 35C1), V5
tag (Invitrogen, mouse monoclonal #46-0705), GST (SIGMA,
mousemonoclonal, #G1160), SUMO1 (BioMol andActiveMotif),
UBC9 (BD Biosciences, mouse monoclonal, #610749, and Santa
Cruz Biotechnology, rabbit polyclonal, #SC-10759), and α-tubulin
(Sigma, mouse monoclonal, clone DM1A). Secondary antibodies
for immunodetection were coupled to Alexa dies (488, 594, 647)
from Molecular Probes (Invitrogen).
For immunoprecipitation, proteins were extracted in the fol-
lowing lysis buffer: Hepes 20mM pH 7.5, β-glycerophosphate
80mM, EDTA 20mM, SDS 0.25%, MgCl2 15mM, NEM 26mM,
1× protease inhibitor cocktail Set III, AEBSF 1mM. Seventy
microliters of protein-G Dynabeads (Invitrogen) were washed
with 500μl of acetate buffer 0.5M pH 5.5 and incubated for 2 h at
4˚Cwith the adequate antibody, and thenwashed twicewith 500μl
PBS. Beads were then incubated with 300μg of proteins for 2 h
at 4˚C. The beads were washed once in 500μl of NaCl 0.5% and
ﬁve times with 500μl TBST. Bound proteins were eluted in 10μl
of 2X-Laemmli sample buffer and the proteins were separated on
a 12.5% SDS polyacrylamide gel and then immunoblotted. The
western blot analyses were performed with the polyclonal UBC9
antibody (1/1000) or the monoclonal Aurora-A antibody (1/200).
For puriﬁcation of histidine-tagged SUMO1 conjugates
under denaturing conditions, we co-transfected HeLa cells with
histidine-tagged SUMO1,V5-tagged Aurora-A variants, and Flag-
UBC9. Cell lysates and Ni–NTA pull-downs were performed as
described (Tatham et al., 2009). V5-tagged Aurora-A was detected
by immunoblotting in both inputs and Ni–NTA puriﬁed frac-
tions using monoclonal anti-V5 at 1/1000, whereas vinculin was
immunodetected usingmousemonoclonal anti-vinculin antibody
only in inputs at 1/1000. Fluorescent signal from the secondary
antibodies was used to quantify V5–Aurora-A signal in each case.
IMMUNOFLUORESCENCE, LIVE CELL ANALYSIS, AND FRAP
Cells were cultured on glass coverslips in standard conditions, and
ﬁxed, depending on the antibody, with either −20˚C methanol for
6min or with 4% PFA plus TritonX-100 0.15% for 10min at room
temperature. Then, the cells were washed in PBS and preincubated
with PBS-3%BSA for 1 h at room temperature to saturate the non-
speciﬁc binding sites and incubated in PBS plus 1.5% BSA with the
primary antibodies for 2 h at room temperature.Afterwashing, the
coverslips were incubated with the matching secondary antibod-
ies for 1 h at room temperature and then mounted in Vectashield
containing 1μg/ml DAPI. Images were obtained using a confo-
cal ultra-spectral microscope (Leica TCS-SP5), a Leica-DMRXA
microscope or an Olympus IX70 microscope controlled by a Delta
Vision SoftWorx (Applied Precision, Issaquah, WA, USA). Image
stacks were deconvolved, quick-projected, and saved as tiff images
to be processed using Adobe Photoshop.
Fluorescence recovery after photobleaching (FRAP) analysis
was performed using a Leica SP5 confocal microscope (Leica,
Inc.) ﬁtted with a 63 objective lens. The live cell chamber was
maintained at 37˚C with 5% CO2. A single Z-section was imaged
before and at set time intervals following the bleach. The bleach
was performed by setting the laser wavelength to 488 nm for EGFP
at maximum power for 75 iterations. The bleached area contained
either the centrosomes (cells at interphase) or both the spindle
MT and poles (mitotic cells). The ﬂuorescence intensities were
determined using LAS AF software (Leica Inc.) in the region of
interest (ROI) corresponding to the bleach area. After completion
of the photobleach, the signal intensity within the ROI was col-
lected at set time intervals. Intensity values were normalized using
the following equation; I t= (X t−Y )/(Z −Y ), where I is the nor-
malized intensity at time t, X is the actual intensity at time t, Y is
the intensity immediately following the photobleach (when t is
equal to zero), and Z is the intensity at the ﬁnal time point. This
sets the initial post-bleach intensity (at t = 0 s) to zero and the ﬁnal
intensity to 1 arbitrary units. Regression analysis was performed
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using the GraphPad Prism software by calculating the least squares
ﬁt using the standard ﬁrst order logarithmic equation. The t1/2
value was the time at which the normalized intensity reaches 0.5
arbitrary units.
Live images were acquired using DeltaVision RT imaging sys-
tem [Applied Precision, LLC; IX70/71 (Olympus)] equipped with
a charge-coupled device camera (CoolSNAP HQ; Roper Scientiﬁc,
Inc.). One micrometer serial Z sections were performed for each
cell and the images were taken in 10min intervals using a 60X
PlanApo N 1.42 N.A. objective. The datasets were deconvolved
using SoftWoRx (Applied Prescision, LLC) software.
For the quantitative analysis of immunoﬂuorescence signals,
acquired images were processed and analyzed using Adobe Photo-
shop CS 8.0 and ImageJ 1.43u. Exogenous EGFP–Aurora-A signal
in mitotic cells was determined as follows: ﬁrst, integrated inten-
sity at MTs and poles was calculated; second, integrated intensity
at the rest of the cell was scored; ﬁnally, the ratio between the two
values was used as the EGFP–Aurora-A signal enrichment at the
spindle. The same approach was followed for the determination
of endogenous α-tubulin signal in the MT re-growth experiments.
Distance between CEP135 signals of mitotic cells was determined
using ImageJ. In all the cases external background was eliminated
using Adobe Photoshop.
STATISTICAL ANALYSES
Data are expressed as mean± SE. Comparisons between the dif-
ferent Aurora-A forms both in transient and stable experiments
were performed using unpaired, two-tail, t -test analysis. Statistical
analyses were performed using Prism 5 for Windows (GraphPad
Software, Inc.). p Values< 0.05 were considered to be statistically
signiﬁcant.
RESULTS
AURORA-A INTERACTS WITH THE SUMO-CONJUGATING ENZYME
UBC9
To identify new Aurora-A interactors, we performed a two-hybrid
screen using full-lengthAurora-A as bait. Out of 20 positive clones
isolated, we identiﬁed one encoding UBC9, a SUMO-conjugating
E2 enzyme. To test the speciﬁcity of this interaction, the full-
length UBC9 cDNA was subcloned into the pGADGH vector
and used as bait with pGBT9–Aurora-A. Only cells co-transfected
with pGADGH–UBC9 and pGBT9–Aurora-A grew on selective
medium. Pull-down assays were undertaken using recombinant
proteins for both molecules [Aurora-A-(His)6 and GST–UBC9].
In the ﬁrst round of experiments, recombinant GST–UBC9 or
GST was incubated with Aurora-A(His)6 and then loaded onto
glutathione-Sepharose beads. As shown in Figure 1A (left panel),
Aurora-A(His)6 was found to bind only to the GST–UBC9 con-
taining sepharose. Binding was also observed in an in vitro histi-
dine pull-down assay (Figure 1A; right panel). In this case recom-
binant GST–UBC9 associated with recombinant Aurora-A(His)6
bound to the column.
We next asked whether endogenous Aurora-A and UBC9 inter-
act in mammalian cells. Using extracts from asynchronous HeLa
cells, we performed immunoprecipitation experiments with anti-
bodies against Aurora-A or UBC9. Consistent with the results
obtained with the recombinant proteins, the anti-UBC9 antibody
FIGURE 1 | UBC9 is a new partner of Aurora-A. (A) UBC9 and Aurora-A
interact in vitro. Recombinant GST–UBC9 protein previously incubated with
or without Aurora-A(His)6 was incubated with nickel–agarose beads
(Ni–NTA–agarose), whereas Aurora-A (His)6 recombinant protein was
incubated in the presence of GST–UBC9 or GST alone and loaded onto
glutathione-sepharose. The presence of Aurora-A and UBC9 was tested by
blotting using anti-Aurora-A and anti-UBC9 antibodies. (B) Aurora-A and
UBC9 interact in vivo. Anti-AurkA antibodies were able to
immunoprecipitate UBC9 (left panels) and anti-UBC9 antibodies
immunoprecipitated Aurora-A proteins (middle panels) from HeLa cell
protein extracts. The same reactions performed with beads only (left lines)
or control IgG (right panels) were unable to immunoprecipitate either UBC9
or Aurora-A.
detected endogenous UBC9 in the anti-Aurora-A pull-down
(Figure 1B; left panel). In addition,Aurora-A protein was detected
by western blot in the UBC9 immunoprecipitates (Figure 1B;
middle panel). Finally, associated proteins were not detected in
immunoprecipitations performed without the Aurora-A or UBC9
antibody or in those performed using IgG (Figure 1B; “beads”
lines and right panel).
AURORA-A IS A NOVEL TARGET FOR SUMOYLATION
To better understand the Aurora-A–UBC9 relationship, we ﬁrst
studied the localization of Aurora-A and UBC9 across the cell
cycle in HeLa cells by immunostaining (Figure 2A). As previously
described, Aurora-A was concentrated on duplicated centrosomes
and, in mitotic cells, it was found to decorate spindle poles, the
midzone, and the cytokinesis bridge (Figure 2A). Interestingly,
UBC9 immunodetection revealed an overlapping signal at centro-
somes at the end of interphase, and at the spindle, midzone, and
cytokinesis bridge during mitosis (Figure 2A).
Because UBC9 was able to bind Aurora-A both in vitro and
in vivo, and both proteins co-localized in the same sub-cellular
compartments, we hypothesized that this mitotic kinase could
be modiﬁed by the addition of SUMO residues. We decided to
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FIGURE 2 | Aurora-A co-localizes with UBC9 and SUMO1 at the spindle
and is SUMOylated both in vitro and in vivo. (A) Aurora-A and UBC9
mainly localize at interphase centrosomes and onto the mitotic spindle.
HeLa cells were ﬁxed and processed for immunodetection of Aurora-A (red)
and UBC9 (green) and observed under a microscope at the indicated
phases of the cell cycle. The Aurora-A and UBC9 signals were coincident on
the centrosomes and the nuclear membrane in interphase, at the spindle in
metaphase and on the cytokinesis bridge at the end of telophase. Note that
whereas Aurora-A is still present at the spindle during anaphase and
telophase (white arrowheads), this is not the case for UBC9. By contrast,
UBC9, and not Aurora-A, is clearly visible at the midzone during anaphase
(yellow arrowheads). (B) Co-localization of Aurora-A and SUMO1.
Endogenous SUMO1 (red) and Aurora-A (green) were detected by
immunoﬂuorescence in HeLa cells. Both proteins co-localize at the spindle
(poles and microtubules) during metaphase. (C) Recombinant Aurora-A
protein was used as substrate in an in vitro SUMOylation assay in the
presence of SUMO1 or SUMO1 mut (a non-conjugatable SUMO1 mutant).
Proteins were separated by reducing 12% SDS-PAGE and visualized with
Coomassie Blue (left panel). Reaction products were used to detect both
Aurora-A and SUMO1 in western blot (right panels). Black arrows indicate
unSUMOylated Aurora-A, red arrows indicate SUMOylated Aurora-A, and
blue arrows mark other proteins included in the reaction that are also
modiﬁed by SUMO1. (D) HeLa cells were co-transfected with the indicated
expression vectors. Forty-eight hours later proteins were isolated and
SUMO1 were conjugates puriﬁed under denaturing conditions. V5-tagged
Aurora-A was detected by immunoblotting in both the inputs and Ni-NTA
puriﬁed fractions, whereas vinculin was immunodetected only in the
inputs. The V5–Aurora-A signal in the Ni–NTA fractions was quantiﬁed after
normalization with the inputs signals for V5–Aurora-A.
speciﬁcally study SUMO1 because it localizes to the mitotic spin-
dle and the spindle midzone whereas SUMO2/3 are found at
centromeres and chromatin during prometaphase and metaphase
(Azuma et al., 2003; Ayaydin and Dasso, 2004; Zhang et al.,
2008b). As shown in Figure 2B, immunodetection revealed the
co-localization of SUMO1 with Aurora-A during metaphase, both
at centrosomes and the mitotic spindle.
Given the fact that Aurora-A, UBC9, and SUMO1 co-localize
onto the same structures, (centrosomes and the mitotic spindle)
during the last stages of interphase and during mitosis,we hypoth-
esized thatAurora-A could be a target of SUMOylation. To test our
hypothesis we ﬁrst performed an in vitro SUMOylation assay using
bacterially expressed and puriﬁedAurora-A protein. Recombinant
Aurora-A protein was incubated with an E1 activating enzyme,
the E2 conjugation enzyme UBC9, and SUMO1 or SUMO1 mut
(a non-conjugatable form of SUMO1) in the presence of ATP. As
shown in Figure 2C, a higher-molecular-weight Aurora-A band
was detected by western blot using anti-Aurora-A. This band was
also immunoreactive with an antibody against SUMO1 and was
not detected when the control (SUMO1 mut) was added to the
reaction instead of wild type SUMO1. Additional non-speciﬁc
bands observed with SUMO1 antibody were also present when
other recombinant proteinswere studied (FigureA1 inAppendix).
To further determinewhether SUMO1 can alsomodifyAurora-
A in vivo,we co-expressed histidine-tagged SUMO1andV5-tagged
Aurora-A constructs in HeLa cells. SUMO1 conjugates were afﬁn-
ity puriﬁed under denaturing conditions with Ni–NTA beads
following previously described procedure (Tatham et al., 2009).
As depicted in Figure 2D, and consistent with the results of the
in vitro SUMOylation assay, a V5 positive band was detected in
cells co expressing V5–Aurora-A and histidine-tagged-SUMO1.
To identify Aurora-A residues capable of SUMO conjugation,
we took advantage of two protein motif ﬁnders: the eukaryotic lin-
ear motif resource (ELM) and the SUMO motif ﬁnder (SUMOFI;
see Materials and Methods). Both predictive tools revealed the
same hit sequence “IKPE” centered on lysine 258 for human
Aurora-A (lysine 249 in mouse). To study the role of this lysine,
we generated an Aurora-A mutant that cannot be modiﬁed by
SUMO at this speciﬁc residue; lysine 249 was replaced by the non-
SUMOylable residue arginine (K249R). Using denaturing condi-
tions to detect SUMO1 conjugates, the same SUMO band that was
observed for wild type Aurora-A was detected upon V5 immun-
odetection in cells over-expressing theK249Rmutant (Figure 2D).
Importantly, wild type V5–Aurora-A was SUMOylated at a higher
level than the K249R mutant. Therefore, this experiment demon-
strated that Aurora-A is SUMOylated at lysine 249 and that other
residues may also be modiﬁed by SUMO binding.
EXPRESSING A MUTANT FORM OF AURORA-A (K249R) INDUCES
MITOTIC DEFECTS
As mentioned above, lysine 249/258 (mouse/human) is a SUMO
site conserved in both mouse and human Aurora-A. Subsequent
analysis of Aurora-A proteins from other species showed that this
putative site for SUMO binding is highly conserved (Figure 3A).
Moreover, this SUMO consensus sequence is also conserved in the
other Aurora kinase members (Figure 3A; bottom) and it has been
shown to participate in the SUMO modiﬁcation of Aurora-B and
-C (Fernandez-Miranda et al., 2010).
To study the importance of this residue in cell function, we
ectopically express its non-SUMOylable form in cell cultures.
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FIGURE 3 | Lack of SUMOylation of Aurora-A alters cell cycle regulation
and increases the ratio of mitotic aberrations. (A) Multiple sequence
alignment of Aurora-A proteins from different species using ClustalW
softwarehttp://www.ch.embnet.org. The SUMO modiﬁcation motif (dashed
box) is highly conserved in all these Aurora-A proteins and in the other two
Aurora family members, but it is not present in Polo-like kinase 4 (Plk4), a
close mitotic relative of these mitotic kinases. (B) HeLa cells were
transiently transfected with an empty vector expressing EGFP (EV) or with
any of the three different EGFP-tagger Aurora-A isoforms (WT, K153,
K249R). Forty-eight hours later, cell cycle proﬁles of transfected cells
(EGFP-positive cells) and the non-transfected cells (NT; EGFP-negative) were
obtained. The histograms and bar-graphs are representative of one of three
independent experiments. (C) Evaluation of aberrant mitoses induced by
Aurora-AK249R by video-microscopy using EGFP-tagged, Aurora-A stable cell
lines. The left panel shows the percentage of abnormal mitoses. Three
different stable clones were used for each Aurora-A variant. A total of 118,
81, and 46 mitoses were analyzed for the wild type, K153M and K249R
variants, respectively. The bars show the average (±SE) of the percentage of
abnormal mitosis found for each clone. The right panel shows the
distribution of mitotic aberrations found for each stable Aurora-A type. Only
the three main abnormal mitotic phenotypes observed, monopolar spindles,
multipolar spindles, and cytokinesis failure, were quantiﬁed. The bars show
data obtained for the three different clones of each variant and pooled into a
single value.
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Asynchronously growing HeLa cells were transfected with EGFP-
tagged expression plasmids for wild type mouse Aurora-A
(Aurora-Awt), kinase-dead Aurora-A (Aurora-AK153M), or the
K249R Aurora-A mutant (Aurora-AK249R). Forty-eight hours
after transfection, cell cycle proﬁles were determined for EGFP-
positive (transfected) and EGFP-negative (untransfected) cells
(Figure 3B). As previously reported (Anand et al., 2003; Jiang
et al., 2003), over-expressing Aurora-A induced a slight accumu-
lation of the 4N population relative to cells transfected with an
empty vector (Figure 3B). A similar accumulation of 4N cells
(25–26%) was found in cells transfected with the kinase-dead or
SUMO-deﬁcient Aurora-A mutants. Wild type and kinase-dead
Aurora-A forms also induced an increase in the number of cells
with DNA content higher than 4N (11.4% and 15.0%) when com-
pared with the controls (4.4% in untransfected cells and 3.6%, in
cells transfected with the empty vector). Interestingly, expressing
theAurora-AK249R mutant induced a signiﬁcantly higher accumu-
lation (22.3%) of cells with DNA content greater than 4N. This
effect was not a consequence of different expression levels because
all Aurora-A isoforms displayed similar levels of expression in
these assays (data not shown).
To further investigate the cellular defects induced by the
K249R mutation, we generated HeLa cell lines that stably
express the wild type, K153M, and K249R isoforms of EGFP-
tagged Aurora-A. Three different clones expressing each Aurora-
A variant were analyzed under a microscope during mitosis as
described in Section“Materials andMethods.”The cells expressing
EGFP–Aurora-AK249R showed the highest percentage of mitotic
abnormalities (19.28± 1.36) compared with EGFP–Aurora-AWT
cells (7.29± 2.51) or EGFP–Aurora-AK153M cells (8.98± 4.70;
Figure 3C; left graph). Detailed analysis of the abnormal mito-
sis occurring in these cells allowed us to identify a speciﬁc
pattern among the EGFP–Aurora-AK249R expressing cells (Supp
videos). Speciﬁcally, HeLa cells stably expressing EGFP–Aurora-
AK249R showed no cytokinesis phenotypes and more multipolar
than monopolar mitoses than did stable EGFP–Aurora-AWT and
EGFP–Aurora-AK153M clones (Figure 3C; right graph).
AURORA-AK249R SHOWS ALTERED LOCALIZATION PATTERNS AND
DYNAMICS AT THE SPINDLE
During mitosis Aurora-A mainly localizes at spindle poles and
along spindle MT. Aurora-A plays a critical role on spindle forma-
tion by promoting MT nucleation and stabilization (Sardon et al.,
2008). To test whether Aurora-A localization requires SUMOy-
lation at K249, we used HeLa cell lines stably expressing EGFP-
tagged Aurora-A variants. As expected, the kinase-dead isoform
of Aurora-A (Aurora-AK153M) displayed reduced mitotic spindle
localization relative to the wild type form (Figure 4A). Simi-
larly, Aurora-AK249R displayed signiﬁcantly reduced localization
to spindle poles and MT (Figure 4A), indicating that SUMOy-
lation (or some other modiﬁcations) at lysine 249 likely plays a
role in the proper localization of Aurora-A at the spindle during
mitosis.
To further characterize the defective localization of Aurora-
AK249R, we analyzed the dynamics of this mutant at spindle poles
and MTs. FRAP was used to compare the relative mobility of
EGFP–Aurora-A variants during interphase and mitosis. Similar
FIGURE 4 | Lack of SUMOylation at K249 alters the dynamics of
Aurora-A at the spindle during mitosis without affecting its kinase
activity or stability. (A) EGFP-tagged Aurora-A was visualized in HeLa cells
stably expressing the wild type, K153M, or K249R variants. EGFP signals
were quantiﬁed at the spindle (poles and microtubules) and in the rest of
the cell. The graph shows the enrichment of EGFP–Aurora-A signal at the
spindle [established as the (spindle EGFP signal)/(remaining cellular EGFP
signal) ratio] in the stable cell lines. Pictures show representative
metaphases for each EGFP-tagged Aurora-A variant. From three different
clones of each variant, a total of 18, 26, and 34 mitoses were detected for
the wild type, K249R, and K153M variants, respectively ***p<0.001. (B)
The same HeLa cells were used in a series of ﬂuorescence recovery after
photobleaching (FRAP) experiments. Representative images of the
recovery of Aurora-AWT and Aurora-AK249R at the centrosomes during mitosis
are shown. Arrows indicate the spindles (poles and microtubules) that were
measured. The graph shows the half-lives obtained using regression
analysis to integrate data from 10 cells each. The half-lives of the
EGFP–Aurora-A variants at mitotic centrosomes were compared using an
unpaired t -test (*p<0.05, **p<0.01). (C)The expression of
EGFP–Aurora-A variants in HeLa stable clones was measured using
time-lapse microscopy. EGFP signals were quantiﬁed for 3 h every 10min
from the ﬁrst frame in which metaphase was detected. Three clones from
each different Aurora-A form were analyzed. Five cells from each clone
were followed in this experiment. Representative frames and the
quantiﬁcation of the three different variants are shown. (D) In vitro kinase
activity toward recombinant MBP of V5-tagged Aurora-A proteins. HEK293
cells were transiently transfected with the indicated V5–Aurora-A
expression vectors and the resulting exogenously expressed proteins were
immunoprecipitated with α-V5 antibody. The 32P-MBP signal was quantiﬁed
considering the total amount of V5–Aurora-A protein in each case.
recovery rates were observed for wild type and Aurora-AK249R at
centrosomes during interphase (Figure A3 in Appendix). During
mitosis, wild type EGFP–Aurora-A was found to move rapidly in
and out of the spindle during mitosis (Figure 4B; left panels) with
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a recovery half-life (t1/2) of 8.67± 0.9 as previously described
(Stenoien et al., 2003). Both the Aurora-AK249R and the Aurora-
AK153M mutants displayed shorter t1/2 recovery times (4.60± 0.2
and 3.49± 1.5 s, respectively; graph in Figure 4B), indicating a
more dynamic rate than that of wild type Aurora-A.
Various mechanisms might be responsible for the abnormal
dynamics and localization shown by Aurora-AK249R. We ﬁrst
explored the possibility that the mutation at lysine 249 could be
affecting the stability of Aurora-A during mitosis. HeLa cell lines
stably expressing EGFP–Aurora-A variants (wild type, K249R,
and K153M) were followed for 3 h after metaphase by video-
microscopy. Quantiﬁcation of the EGFP signal revealed that all
three Aurora-A isoforms showed a similar pattern of expres-
sion/degradation frommitosis to the beginning of G1 (Figure 4C).
Because Aurora-A localization requires its kinase activity (Sar-
don et al., 2008), we also tested whether the K249R mutation
affects Aurora-A kinase activity. To evaluate the kinase activ-
ity of the Aurora-A variants, HeLa cells were transfected with
V5-tagged expression vectors for the different Aurora-A variants
(WT, K153M, and K249R). Then, the exogenous proteins were
immunoprecipitated and tested for their activity toward the sub-
strate MBP. The kinase-dead isoform K135M was not able to
efﬁciently phosphorylate this substrate, the K249R isoform was
able to phosphorylate MBP at the same level as the wild type pro-
tein (Figure 4D), suggesting no intrinsic deﬁciencies in kinase
activity in this isoform. Thus, we conclude that the abnormal
localization and dynamics of theAurora-AK249R protein is a conse-
quence of neither decreased intrinsic kinase activity nor increased
degradation.
ECTOPIC EXPRESSION OF AURORA-AK249R AFFECTS SPINDLE
FORMATION DURING MITOSIS
The major phenotypes resulting from the expression of the
Aurora-AK249R form are the formation of monopolar and mul-
tipolar spindles (43 and 57% out of the abnormal mitoses vs.
33 and 50% in the case of Aurora-AWT; Figure 3C). As both
abnormalities might be due to defects on spindle formation and
Aurora-A function has been shown to be crucial to the nucleating
capacity of centrosomes during mitosis (Gergely, 2002; Barr and
Gergely, 2007), we analyzed microtubule nucleation in HeLa cells
stably expressing wild type and variants versions of EGFP-tagged
Aurora-A. MTs were depolymerized by incubating the cells on ice
for 40min. Then, the cells were warmed to 37˚C and α-tubulin was
monitored by immunoﬂuorescence 3 and 10min later to quantify
MT re-growth (Figure 5A). Interestingly, EGFP–Aurora-AK249R
expressing cells were not able to re-polymerize MTs as efﬁciently
as cells expressing either EGFP–Aurora-AWT or EGFP–Aurora-
AK153M (Figure 5B). This difference between α-tubulin signal
detected in Aurora-AWT and Aurora-AK249R cells was signiﬁcant
both 3 and 10ml after the cells were re-warmed. To analyze the
formation of spindles in the different stable cell lines, CEP135
was detected to visualize spindle poles (Figure 5A) and the spin-
dle length was quantiﬁed (Figure 5C). HeLa cells stably expressing
EGFP–Aurora-AK249R showed shorter spindles thanHeLa cells sta-
bly expressing either EGFP–Aurora-AWT, EGFP–Aurora-AK153M,
or only EGFP. These differences, which were signiﬁcant at both
FIGURE 5 | Lack of SUMOylation of Aurora-A affects MT nucleation
and spindle formation during mitosis. (A) Analysis of spindle formation in
cells stably expressing Aurora-Awt, Aurora-AK249R, or Aurora-AK153M. The cells
were incubated with nocodazole for 6 h to enrich the culture for mitotic
cells, and MTs were depolymerized by incubating the cells on ice for 40min.
Then, MTs were allowed to grow by re-warming the cells at 37˚C, and the
cells analyzed for recruitment of endogenous α-tubulin to the spindle and
centrosome localization of CEP135 detection. Representative images taken
at 3 and 10min post re-warming. Quantiﬁcation and statistical analysis of
the results of this experiment are shown in (B,C). (B) Graphs show the
quantiﬁcation of α-tubulin signal obtained at the spindle, as described in
Section “Materials and Methods,” from each EGFP-Aurora-A cell line. Two
different clones of the control (empty) and Aurora-A variants (WT, K153M,
and K249R) were analyzed. A total of 36 cells were studied for each type.
For the two time point analyzed (3 and 10min post re-warming) α-tubulin
signal was lower among the Aurora-AK249R cells than in the Aurora-AWT ones.
(C) Graphs display spindle length in the same HeLa cells that were studied
in (B). Spindle length was scored as the distance between the two major
CEP135 signals in each mitotic cell. At 3 and 10min after re-warming, the
distance between spindle poles was signiﬁcantly shorter in Aurora-AK249R
expressing cells when compared with wild type and kinase-dead cell lines.
(D) Spindle length was also analyzed in the same EGFP–Aurora-A cell lines
growing asynchronously. Spindle length was determined as the distance
between the two major EGFP–Aurora-A signals detected at metaphase,
which should be associated with spindle poles. Three clones from each
Aurora-A variant were studied. A total of 28, 42, and 42 mitosis were
analyzed for the wild type, K249R, and K153M variants, respectively. Again,
the spindle length observed in the Aurora-AK249R cells was shorter than that
in the stable cell lines expressing wild type or kinase-dead Aurora-A
variants. In all the cases data from a minimum of 20 EGFP-positive cells
were compared using unpaired t -tests. Signiﬁcant differences are indicated
as follows: *p<0.05, **p<0.01, and ***p<0.001.
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3 and 10min post re-warming, were more pronounced 10min
after the MT were allowed to re-grow (Figure 5C). To gain further
support for these results, we studied these EGFP-tagged AurkA
stable cell lines by video-microscopy, while they were growing
asynchronously. The spindle length of bipolar metaphase cells was
established by calculating the distance between poles that were
localized by EGFP–AurkA visualization. As in the MT-re-growth
experiment, EGFP–Aurora-AK249R cells showed shorter spindles
when compared with EGFP–Aurora-AK153M or EGFP–Aurora-
AWT cells (Figure 5D). We conclude that over-expression of the
K249R Aurora-A protein, but not the wild type or kinase-dead
forms, results in a weaker microtubule network and is associated
with a defective spindle formation.
AURORA-AK249R DISPLAYS ALTERED TUMORIGENIC AND APOPTOTIC
PROPERTIES
Ectopic over-expression of Aurora-A allows Rat1 ﬁbroblasts to
grow in soft agar (Bischoff et al., 1998) and cooperates with H-Ras
in the transformation of mouse ﬁbroblasts (Tatsuka et al., 2005).
To examine if lysine 249 has any effect on the role of Aurora-A
in inducing the malignant phenotype, we performed a series of
focus-formation experiments co-transfecting an oncogenic form
of H-Ras with Aurora-A variants. As previously reported (Tat-
suka et al., 2005), the wild type form of Aurora-A potentiates
H-RasV12-induced transformation (Figure 6A). Importantly, co-
transfection of H-RasV12 with the Aurora-AK249R variant signif-
icantly increased the number of foci when compared with the
wild type form (1.7 fold induction). This increased malignant
phenotype was not due to different levels of expression of the
exogenous Aurora-A variants used in this experiment (Figure A4
in Appendix). Given the importance of Aurora-A in tumorigen-
esis, we wanted to ascertain the cause of this difference between
the over-expression of Aurora-AK249R and Aurora-AWT. Because
Aurora-AK249R cells did not show signiﬁcant differences when
compared with Aurora-AWT expressing cells in colony formation
assays (data not shown), we discarded differential proliferation
efﬁciency as the cause of themore aggressivemalignant phenotype.
We then explored the possibility that Aurora-AK249R may induce
high levels of genomic instability as also suggested by the increase
inmitotic abnormalities observed uponAurora-AK249R expression
(Figure 3). The number of chromosomes per cell was determined
in metaphase cells from foci obtained upon co-transfection of H-
RasV12 and Aurora-A. The control mouse ﬁbroblasts used in this
experiment had a diploid/tetraploid, mixed karyotype showing
an average chromosome number of 48.04± 2.38 chromosomes
(Figure 6B). Foci obtained upon H-RasV12 transfection signiﬁ-
cantly differed from those transfected with the empty vector (aver-
age chromosome number of 77.75± 2.37; p< 0.001). Foci from
H-RasV12/Aurora-AWT co-transfected cells showed chromosome
numbers (83.71± 3.22) signiﬁcantly higher than those observed
in the control cells (p< 0.0001), but they showed no statistical
differences when compared with the foci transfected only with H-
RasV12 (p = 0.155). Interestingly, co-transfection with the K249R
form of Aurora-A induced the most dramatic aneuploid phe-
notype. Foci from H-RasV12/Aurora-AK249R co-transfected cells
showed an average chromosome number of 97.96± 5.07, which
signiﬁcantly differed from the average chromosome numbers
FIGURE 6 | Aurora-A SUMOylation and tumorigenesis. (A) Effects of
Aurora-AK249R over-expression on H-RAS-induced transformation in NIH-3T3
cells. Control and Aurora-A expression vectors were co-transfected with an
activated G12V–H-RAS vector. Forty-eight hours, post-transfection, the cells
were split one to three and kept in culture with 5% calf serum. Two weeks
later, dishes were ﬁxed with ethanol and stained with crystal violet.
Representative images are shown for each point. A bar graph shows the
quantiﬁcation of the number of foci. (B) Lack of SUMOylation of Aurora-A at
lysine 249 increases aneuploidy in H-RAS-transformed mouse ﬁbroblasts.
Chromosomes were counted in a minimum of 20 metaphase cells from
foci obtained upon transfection with the indicated expression plasmids.
Three different foci were analyzed per each transfection type. (C) Lack of
SUMOylation increases the taxol chemoresistance induced by Aurora-A
over-expression in HeLa cells. HeLa cells stably expressing a control empty
vector or EGFP-tagged Aurora-A variants were treated with 150 nM taxol for
48 h. At the end of the treatment, the cells were incubated with propidium
iodide (0.02mg/ml) to determine the number of dead cells (positive for PI).
A bar graph shows the quantiﬁcation for three different clones of each type
in one of the two experiments carried out. In all the previous graphs,
signiﬁcant differences are indicated as follows: *p<0.05, **p<0.01, and
***p<0.001.
found among control cells (p< 0.0001), foci transfected with H-
Ras V12 (p = 0.0003) and foci co-transfected with H-Ras V12 and
Aurora-AWT (p = 0.0143). These results suggested that the over-
expression of Aurora-AK249R cooperates with H-RasV12 in the
transformation of mouse ﬁbroblasts by inducing signiﬁcantly high
levels of aneuploidy.
Finally, we explored the effect of expressing the Aurora-A
mutants on the reported resistance to taxol induced by Aurora-
A over-expression (Anand et al., 2003). We treated three HeLa
clones stably expressing three different EGFP–Aurora-A variants
at different levels (Figure A2 in Appendix) with taxol (150 nM)
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for 48 h. The percentage of apoptotic cells was then measured
using propidium iodide (PI) staining and ﬂow cytometry to quan-
tify the PI positive (dead) population. As shown in Figure 6C,
stable over-expression of Aurora-A induces a signiﬁcant resis-
tance to taxol-induced apoptosis, as previously reported for the
transient over-expression of wild type Aurora-A in HeLa cells
(Anand et al., 2003). Over-expression of the K249R mutant is
also associated with a signiﬁcant protection from the Taxol-
induced death (Figure 6C). Interestingly, the protective phenotype
is stronger, although not signiﬁcant (p = 0.203), in Aurora-AK249R
over-expressing cells than in those over-expressing Aurora-AWT.
On the other hand, the kinase-dead-mutant did not induce the
resistance phenotype because the cells stably expressing Aurora-
AK153M did not differ from the control cells stably transfected with
an empty vector. The percentage of dead cells was signiﬁcantly dif-
ferent in the Aurora-AK153M and Aurora-AK249R clones suggesting
that the kinase activity of the protein is necessary for the K249R
Aurora-A form to induce the resistance to taxol-induced apoptosis.
In summary, we conclude that the lysine to arginine mutation
at residue 249 of mouse Aurora-A is associated with a high rate
of mitotic abnormalities that in turn induces segregation errors
that result in severe aneuploidy and cooperate with H-RAS in
the induction of malignancy. Furthermore, our data suggest that
the over-expression of K249R Aurora-A may protect cells from
apoptotic responses to antimitotic poisons such as Taxol.
DISCUSSION
SUMOylation is a reversible process involved in the regulation of
multiple protein functions. This post-translational modiﬁcation
affects the sub-cellular localization, activity, and/or stability of an
increasing number of substrates. Increasing evidence in recent
years has associated SUMOylation with the regulation of multi-
ple cellular processes including meiosis and mitosis (De Carvalho
and Colaiacovo, 2006; Dasso, 2008). SUMO peptide modiﬁca-
tions are involved in the nucleocytoplasmic shuttling of centrin-2
(Klein and Nigg, 2009), the cell cycle-dependent regulation of
Borealin (Klein et al., 2009), the association of CENP-E with kine-
tochores (Zhang et al., 2008b), mitotic spindle asymmetry and
the spindle-assembly checkpoint in yeast via Kar9 (Leisner et al.,
2008), and the resolution of sister centromeres by topoisomerase
II alpha (Dawlaty et al., 2008). Here, we report that Aurora-A
kinase interacts with UBC9, the only E2 conjugating enzyme of
the SUMOylation pathway. We observed the interaction of these
two proteins both in the two-hybrid system and in biochemical
assays in mammalian cells. SUMOylation seems to affect only a
small fraction of Aurora-A (Figures 2C,D) as also reported for
Aurora-B (Fernandez-Miranda et al., 2010) andmany other targets
(Geiss-Friedlander and Melchior, 2007).
Aurora-A contains a highly conserved SUMO target site that
is also present in other Aurora family members. Indeed, we and
others previously observed that modiﬁcation by SUMO plays a
critical role in the regulation of Aurora-B function (Fernandez-
Miranda et al., 2010; Ban et al., 2011). Aurora-B can bind SUMO
peptides in vitro and the expression of a SUMO-null form
of Aurora-B results in abnormal chromosome segregation and
failed cytokinesis. We previously proposed that SUMOylation of
Aurora-B modulates its function by mediating the extraction of
chromosome passenger complexes from chromosome arms dur-
ing prometaphase (Fernandez-Miranda et al., 2010). Here, we
show that the expression of an Aurora-A that cannot be SUMOy-
lated at lysine 249 induces a signiﬁcant increase in the number
of mitotic abnormalities found among proliferating HeLa cells.
These Aurora-AK249R-induced mitotic aberrations are speciﬁcally
enriched in multipolar spindles suggesting that spindle regulation
is defective. Aurora-A, UBC9, and SUMO1 all decorate both cen-
trosomes and the mitotic spindle, which favor the hypothesis that
these proteins speciﬁcally interact in these sub-cellular structures
regulating spindle function. Moreover, Aurora-AK249R expressing
cells are characterized by an abnormal α-tubulin expression pat-
tern in MT-re-growth experiments and by defective formation of
the spindle. The role of Aurora-A in centrosome function and
spindle assembly has been widely established in Drosophila, C. ele-
gans, Xenopus egg extracts, and human cells (Hannak et al., 2001;
Giet et al., 2002;Andrews et al., 2003). A recent study performed in
Xenopus egg extract has demonstrated that Aurora-A is necessary
for the generation of a proper spindle through its role at the cen-
trosome of recruiting factors involved in microtubule nucleation
and stabilization (Sardon et al., 2008).
However, the identity of the Aurora-A partner or substrate
involved in the abnormal spindle formation induced upon over-
expressionof theAurora-AK249R mutant remainunknown.MCAK
and ch-TOG (also known as CKAP5) emerge as two main can-
didates. MCAK, a negative regulator of MT plus end growth is
regulated at the centrosomes byAurora-Aphosphorylation to con-
trol Ran-dependent spindle formation (Zhang et al., 2008a). On
the other hand, Aurora-A phosphorylates and localizes TACC3 to
spindle poles (Kinoshita et al., 2005; Leroy et al., 2007), which
is necessary for ch-TOG localization to spindle MTs (Gergely
et al., 2003). Moreover, both MCAK and ch-TOG abnormally
accumulate at the spindle of Aurora-A depleted cells (De Luca
et al., 2008). All these preliminary results indicate that Aurora-A,
MCAK, and ch-TOG are part of a common pathway that controls
spindle formation and integrity. How the SUMO modiﬁcation of
Aurora-A is involved in the regulation of this pathway is still an
open question. One attractive hypothesis could be that the SUMO
modiﬁcation allows Aurora-A to anchor more ﬁrmly to spindle
MTs by interacting with the SUMO interacting motifs (SIMs) that
are predicted to be present in the ch-TOG sequence (unpublished
data). Although we believe that the possibility that ch-TOG acts
as a docking platform for SUMOylated Aurora-A deserves fur-
ther investigation, other possible mechanistic explanations for the
abnormal phenotype induced by Aurora-AK249R should not be
ruled out. For instance, it is also possible that the SUMOylation of
Aurora-A modulates its kinase activity. Indeed, some of the phe-
notypes induced by the Aurora-AK249R mutant were coincident
with the ones induced by the kinase-dead Aurora-A variant; e.g.,
the altered localization and dynamics at the spindle during mito-
sis (Figures 4A,B). However, similarly to what has been reported
forAurora-B (Fernandez-Miranda et al., 2010), theAurora-AK249R
mutant does not display reduced kinase activity (Figure 4D) and
differs from the kinase-dead inmany other phenotypes induced by
their over-expression (MT nucleation and spindle length among
others). It is also possible that the K249R mutation is affect-
ing Aurora-A function through a mechanism other than SUMO
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modiﬁcation. For instance, thismutation could affect the structure
of the protein or modiﬁcation by other post-translational regula-
tors such as ubiquitination. However, the predicted structures for
both wild type Aurora-A and K249R do not differ in any of the
major catalytic or regulatory domains of this kinase (unpublished
results). In addition, the Ubc9–Aurora-A relationship and the
actual SUMOylation of Aurora-A described here together with the
fact that this residue is highly conserved and regulated by SUMO
in other Aurora family members (Fernandez-Miranda et al., 2010)
favor the idea that SUMOylation, rather than ubiquitination, is
the post-translational modiﬁcation affecting lysine 249. All these
considerations suggest that the functional defects induced by the
expression of the Aurora-AK249R protein are likely a consequence
of the lack of SUMO modiﬁcation of this speciﬁc residue, which
in turn alters the localization of Aurora-A.
Given the fact that SUMOylation is involved in a variety of
cellular processes, links between this post-translational modiﬁ-
cation and cancer and metastasis can be postulated. In fact, the
SUMO pathway has been described to be associated with tumori-
genesis atmultiple levels (Katayama et al., 2003; Seeler et al., 2007).
Increased levels of UBC9, the SUMO E3 protein PIAS3, the SUMO
E1 enzyme, and the SUMO protease SENP1 are found in several
human cancers and, in some cases, they are associated with lower
survival rates (Mcdoniels-Silvers et al., 2002; Lee andThorgeirsson,
2004;Wang andBanerjee, 2004; Jacques et al., 2005;Mo et al., 2005;
Cheng et al., 2006). The association of both pro-SUMOylation and
pro-deSUMOylation molecules with cancer indicates a complex
relationship between this post-translational modiﬁcation network
and tumorigenesis. Indeed, SUMOylation can regulate the activi-
ties of both tumor suppressor proteins, including p53, pRB, p63,
and p73, and oncogenes such as murine double minute 2 (Mdm2),
PML, c-myc, and Wnt-1 (Seeler et al., 2007). Our results further
support a role of SUMOylation in the acquisition of malignant
properties through the modiﬁcation of the putative oncogene
Aurora-A. First, blocking SUMOylation by mutating lysine 249
is associated with higher susceptibility to cellular transformation
by RAS oncogenes. Second, lack of SUMOylation of Aurora-A at
lysine 249 results in decreased apoptosis in the presence of mitotic
poisons.
Taken together, our data suggest that Aurora-A is modiﬁed by
SUMO residues through its interaction with UBC9. Conjugation
of SUMOresidues at lysine 249mayhelp to control the localization
of this kinase at the spindle. This modiﬁcation in turn modu-
lates the biological function of Aurora-A in a signaling pathway
that leads to proper MT nucleation and spindle formation during
mitosis. This new regulatory mechanism may have relevant impli-
cations in both tumor development and the cellular responses to
mitotic poisons currently used in cancer therapy.
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APPENDIX
FIGUREA1 | Non-specific SUMO1-reactive bands are detected upon
in vitro SUMOylation. In vitro SUMO1 reactions were performed for
Aurora-A and p53 as in Figure 2C. In both cases, the resulting bands were
visualized by Coomassie (CBB) staining (left panel). Immunoblotting using an
anti-SUMO1 antibody detects a number of common bands (blue arrows) that
do not correspond to the expected SUMOylated bands (red arrows).
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FIGUREA2 | Stable HeLa cell lines used in this work for the analysis of
K249. EGFP-tagged expression vectors were used to transfect wild-type,
K249R, and K153M Aurora-A into HeLa cells. G418-resistant, EGFP-positive
colonies were expanded and Aurora-A exogenous expression was
established by western blotting and immunoﬂuorescence. (A) Representative
clones for the expression of high and low levels of EGFP–Aurora-A (green)
variants. DNA (blue) and α-tubulin (red) are also shown. Mouse monoclonal
anti-α-tubulin (clone DM1A) from SIGMA was used at 1/1000. (B) Detection
of EGFP–Aurora-A proteins in stable cell lines by immunoblotting. Three
different clones for each Aurora-A variant are shown. Vinculin detection and
Ponceau staining are shown as loading controls. The antibodies and dilutions
used were as follows: anti-EGFP (Roche, mouse monoclonal; clones 7.1 plus
13.1) at 1/1000 and anti-vinculin (SIGMA mouse monoclonal; clone hVIN-1) at
1/1000.
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FIGUREA3 | Lack of SUMOylation at K249 does not alter
Aurora-A dynamics at centrosomes during interphase. HeLa cells
stably expressing EGP–AurkA variants were used in a series of
ﬂuorescence recovery after photobleaching (FRAP) experiments. The
upper panels show representative images of Aurora-AWT and
Aurora-AK249R recovery at centrosomes during interphase. A graph
shows the half-lives obtained using regression analysis to integrate
data from 10 cells each. The half-lives of EGFP–Aurora-A variants at
interphase centrosomes were not different when compared using a
unpaired t -test.
FIGUREA4 | Foci induced upon Ras plus Aurora-A transfection show
similar expression levels of exogenous Aurora-A. Detection of V5-Aurora-A
proteins in stable cell lines by immunoblotting is shown for three different foci
of the indicated types. Anti-V5 tag (Invitrogen, mouse monoclonal #46-0705)
was used to detect exogenous Aurora-A fused to V5. Vinculin detection and
Ponceau staining are shown as loading controls.
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